Published in Mol Ther on August 17, 2010
The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet (2011) 1.18
The expanding universe of transposon technologies for gene and cell engineering. Mob DNA (2010) 1.08
Gene therapy for hemophilia. Front Biosci (Landmark Ed) (2015) 0.94
A Hyperactive Transposase Promotes Persistent Gene Transfer of a piggyBac DNA Transposon. Mol Ther Nucleic Acids (2012) 0.93
Retargeting transposon insertions by the adeno-associated virus Rep protein. Nucleic Acids Res (2012) 0.92
Genetic therapies for cystic fibrosis lung disease. Hum Mol Genet (2011) 0.91
Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Mol Cancer (2011) 0.89
Cell-free transmission of human adenovirus by passive mass transfer in cell culture simulated in a computer model. J Virol (2012) 0.89
DNA transposon-based gene vehicles - scenes from an evolutionary drive. J Biomed Sci (2013) 0.89
A Novel Adenoviral Hybrid-vector System Carrying a Plasmid Replicon for Safe and Efficient Cell and Gene Therapeutic Applications. Mol Ther Nucleic Acids (2013) 0.88
Integration profile and safety of an adenovirus hybrid-vector utilizing hyperactive sleeping beauty transposase for somatic integration. PLoS One (2013) 0.84
piggyBac-mediated phenotypic correction of factor VIII deficiency. Mol Ther Methods Clin Dev (2014) 0.82
Standard free droplet digital polymerase chain reaction as a new tool for the quality control of high-capacity adenoviral vectors in small-scale preparations. Hum Gene Ther Methods (2015) 0.82
Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models. Virus Genes (2017) 0.81
Hybrid adeno-associated viral vectors utilizing transposase-mediated somatic integration for stable transgene expression in human cells. PLoS One (2013) 0.81
Hybrid nonviral/viral vector systems for improved piggyBac DNA transposon in vivo delivery. Mol Ther (2015) 0.79
Prolonged expression of secreted enzymes in dogs after liver-directed delivery of <i>Sleeping Beauty</i> transposons: implications for non-viral gene therapy of systemic disease. Hum Gene Ther (2017) 0.76
Mobilization of DNA transposable elements from lentiviral vectors. Mob Genet Elements (2011) 0.75
An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells. Front Bioeng Biotechnol (2017) 0.75
Adenoviral Vectors for Hemophilia Gene Therapy. J Genet Syndr Gene Ther (2013) 0.75
Preclinical and clinical advances in transposon-based gene therapy. Biosci Rep (2017) 0.75
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell (1997) 8.68
The dog genome: survey sequencing and comparative analysis. Science (2003) 5.84
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol (1995) 5.67
MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity (1994) 4.65
A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A (1996) 3.89
Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet (2009) 3.86
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med (1999) 3.39
High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol (2005) 3.10
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science (1993) 2.95
Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost (2006) 2.81
Improved system for helper-dependent adenoviral vector production. Mol Ther (2003) 2.71
Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet (1998) 2.65
Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A (1995) 2.33
Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther (2004) 2.32
Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol (2002) 2.31
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood (2007) 2.28
Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A (2001) 2.20
Frequency and stability of chromosomal integration of adenovirus vectors. J Virol (1999) 2.18
Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood (2008) 1.98
Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model. J Thromb Haemost (2006) 1.97
Site-directed transposon integration in human cells. Nucleic Acids Res (2007) 1.74
Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol (1998) 1.72
In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci U S A (1994) 1.70
Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol (2004) 1.70
Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A (1989) 1.68
High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther (1998) 1.67
Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J Virol (1996) 1.61
Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther (2007) 1.50
A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol (1997) 1.42
Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther (2008) 1.40
Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A (2005) 1.36
Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther (2005) 1.32
A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood (2002) 1.18
Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood (2003) 1.13
Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J Virol (2003) 1.06
Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther (2007) 1.05
A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood (2003) 1.00
A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc (2009) 0.97
Correction of chromosomal mutation and random integration in embryonic stem cells with helper-dependent adenoviral vectors. Proc Natl Acad Sci U S A (2005) 0.97
Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B. Hum Gene Ther (2009) 0.96
In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice. Mol Ther (2000) 0.90
Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol Ther (2001) 0.89
Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J Gene Med (2008) 0.87
Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. Gene Ther (2006) 0.87
Persistence of high-capacity adenoviral vectors as replication-defective monomeric genomes in vitro and in murine liver. Hum Gene Ther (2009) 0.84
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med (2006) 13.51
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature (2006) 10.95
Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 6.95
The draft genome of the transgenic tropical fruit tree papaya (Carica papaya Linnaeus). Nature (2008) 5.54
RNA interference in adult mice. Nature (2002) 5.33
Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol (2007) 5.04
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther (2006) 4.64
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2002) 4.60
A nonviral minicircle vector for deriving human iPS cells. Nat Methods (2010) 4.42
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol (2009) 3.70
Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol (2004) 3.65
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood (2002) 3.45
Human tRNA-derived small RNAs in the global regulation of RNA silencing. RNA (2010) 3.40
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol (2005) 3.28
Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol (2003) 3.15
High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol (2005) 3.10
LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med (2004) 3.00
Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther (2003) 2.95
The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol (2006) 2.94
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J Clin Invest (2011) 2.83
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A (2007) 2.56
Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol (2002) 2.54
Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther (2003) 2.49
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat Biotechnol (2002) 2.31
Gene amplification confers glyphosate resistance in Amaranthus palmeri. Proc Natl Acad Sci U S A (2009) 2.23
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood (2005) 2.12
Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol (2005) 2.09
Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther (2005) 2.06
Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood (2008) 2.01
Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther (2008) 2.01
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther (2002) 1.98
Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells. Mol Cell Biol (2004) 1.97
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J Clin Invest (2010) 1.91
The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. Cell (2012) 1.84
Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res (2012) 1.84
Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood (2004) 1.78
Site-directed transposon integration in human cells. Nucleic Acids Res (2007) 1.74
A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol (2002) 1.71
Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology (2011) 1.66
Chromatin immunoprecipitation cloning reveals rapid evolutionary patterns of centromeric DNA in Oryza species. Proc Natl Acad Sci U S A (2005) 1.64
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood (2003) 1.62
Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res (2010) 1.58
Repeatless and repeat-based centromeres in potato: implications for centromere evolution. Plant Cell (2012) 1.54
Adenovirus transduction is required for the correction of diabetes using Pdx-1 or Neurogenin-3 in the liver. Mol Ther (2007) 1.51
Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol Ther (2002) 1.51
Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther (2007) 1.51
Blood outgrowth endothelial cell migration and trapping in vivo: a window into gene therapy. Transl Res (2009) 1.50
Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods (2012) 1.50
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood (2010) 1.50
Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood (2010) 1.49
Silencing of episomal transgene expression in liver by plasmid bacterial backbone DNA is independent of CpG methylation. Mol Ther (2008) 1.49
The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood (2012) 1.48
Canine specific ELISA for coagulation factor VII. Vet J (2011) 1.46
Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation (2009) 1.45
Calpain is required for the rapid, calcium-dependent repair of wounded plasma membrane. J Biol Chem (2006) 1.43
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J (2009) 1.43
Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol Ther (2003) 1.42
Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther (2006) 1.41
Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology (2010) 1.41
TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem (2010) 1.40
Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol Ther (2007) 1.40
In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther (2002) 1.39
Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther (2010) 1.38
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood (2012) 1.38
Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol (2002) 1.37
Nonhomologous-end-joining factors regulate DNA repair fidelity during Sleeping Beauty element transposition in mammalian cells. Mol Cell Biol (2003) 1.37
Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol (2006) 1.36
Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant (2010) 1.36
The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol (2007) 1.35
Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther (2010) 1.35
Sequencing papaya X and Yh chromosomes reveals molecular basis of incipient sex chromosome evolution. Proc Natl Acad Sci U S A (2012) 1.35
The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proc Natl Acad Sci U S A (2002) 1.34
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest (2007) 1.34
Capped small RNAs and MOV10 in human hepatitis delta virus replication. Nat Struct Mol Biol (2008) 1.34
In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest (2003) 1.33
Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem (2008) 1.32
Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood (2010) 1.32
Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector. Hum Gene Ther (2005) 1.32
The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther (2008) 1.31